For the Inventor, By the Inventor

Enter assignee name

Seattle, WA, United States of America

Zymogenetics, Inc.

USPTO Granted Patents = 723

% Expired Patents = 25.4

CIPO Patents = 42

EPO Patents = 71

Trademarks = 1

Forward Citations = 9,798

Loading Chart...

Loading Chart...

289 inventors (with patents filed for the assignee):

Paul O Sheppard (143 out of 164 patents)

Scott R Presnell (118 out of 129 patents)

Wayne R Kindsvogel (72 out of 104 patents)

4. Darrell C Conklin (63 out of 63 patents)

5. Cindy A Sprecher (61 out of 65 patents)

6. Donald C Foster (60 out of 72 patents)

7. Stephen R Jaspers (54 out of 57 patents)

8. Jane A Gross (51 out of 52 patents)

9. Julia E Novak (50 out of 56 patents)

10. Wenfeng Xu (48 out of 48 patents)

11. Brian A Fox (46 out of 49 patents)

12. Janine M Bilsborough (45 out of 55 patents)

13. Kevin M Klucher (45 out of 45 patents)

14. Paul D Bishop (42 out of 59 patents)

15. Angela K Hammond (42 out of 42 patents)

Core Competencies:

IL-31

IL-17A

IL-17F

Pruritus

Inflammation

Monoclonal Antibodies

Autoimmune Diseases

Cytokine Receptors

BCMA Protein

TACI-Fusion Proteins

Neuronal Inflammation

ZCYTOR17

723 patents: Sort by Forward Citations

1. 11542327 - Methods of treating pruritic disease with IL-31 monoclonal antibodies (2023-01-03),

2. 11312779 - Methods of treating prurigo nodularis using anti-IL-31RA antibody compositions (2022-04-26),

3. RE48370 - Levels of BCMA protein expression on B cells and use in methods of treating systemic lupus erythematosus (2020-12-28),

4. 10640575 - Use of IL-17A and IL-17F cross-reactive monoclonal antibodies for treating inflammatory diseases (2020-05-05),

5. 10640559 - Nucleic acid molecules encoding humanized IL-31 monoclonal antibodies (2020-05-05),

6. 10611846 - Methods of treating skin disorders using anti-IL-31RA antibodies (2020-04-07),

7. 10570187 - Soluble hybrid Fcγ receptors and related methods (2020-02-25),

8. 10562967 - Treating inflammation with IL-17/IL-23 bispecific antibodies (2020-02-18),

9. 10434173 - Use of IL-31 monoclonal antibodies for treating pruritus (2019-10-08),

10. 10273297 - Use of IL-31 monoclonal antibodies for reducing pruritus (2019-04-30),

11. 10259868 - Methods of treating atopic dermatitis with IL-31 monoclonal antibodies (2019-04-16),

12. 10227415 - Methods of producing a zcytor17 heterodimeric cytokine receptor (2019-03-12),

13. 10023656 - Methods of treating inflammation using IL-17A and IL-17F cross-reactive monoclonal antibodies (2018-07-17),

14. 10005837 - B7 family member zB7H6 and related compositions and methods (2018-06-26),

15. 10000563 - Monoclonal antibodies that bind both IL-17A and IL-17F (2018-06-19),

Company Overview

Zymogenetics, Inc., based in Seattle, WA, specializes in the development of monoclonal antibodies targeting key cytokines involved in autoimmune diseases. The company focuses on innovative therapies addressing conditions related to IL-31, IL-17A, and IL-17F, which are pivotal in managing pruritus and inflammation. Through its advanced research in cytokine receptors, Zymogenetics aims to provide effective solutions for patients suffering from various inflammatory disorders, contributing to the evolving landscape of biopharmaceuticals.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

723 Patents

#3 in Seattle, WA

#11 in Washington

#697 in US

#1,376 in the World

Seattle, WA, United States of America

Zymogenetics, Inc.

Forward Citations = 9,798

289 inventors:

Paul O Sheppard (143 out of 164 patents)

Scott R Presnell (118 out of 129 patents)

Wayne R Kindsvogel (72 out of 104 patents)

4. Darrell C Conklin (63 out of 63 patents)

5. Cindy A Sprecher (61 out of 65 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Zymogenetics, Inc.. Retrieved from https://idiyas.com/company/zymogenetics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…